Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

(2015) Anwar R. Padhani et al.   NEOPLASIA

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

(2010) Benjamin M. Ellingson et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas

(2010) Benjamin M. Ellingson et al.   JOURNAL OF NEURO-ONCOLOGY

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri

(2009) Benjamin M. Ellingson et al.   JOURNAL OF NEURO-ONCOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment

(2009) Whitney B. Pope et al.   RADIOLOGY

Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival

(2008) Daniel A. Hamstra et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY